Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis from a Phase 3 Randomized Clinical Trial (MELODY)

• 2024

  Log in to bookmark this resource.

  Log in
• Doug Arbetter; Vancheswaran Gopalakrishnan; Anastasia Aksyuk; Bahar Ahani; Yue Chang; Ron Dagan
PMID: 39656748DOI: https://doi.org/10.1093/cid/ciae596

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article compares the effects of nirsevimab, a monoclonal antibody, with a placebo in preventing lower respiratory tract infections caused by the respiratory syncytial virus (RSV) in infants. It describes how nirsevimab effectively reduces RSV infections without increasing other viral infections. The trial involved 3,012 participants and showed that those receiving nirsevimab had fewer RSV-related hospitalizations compared to those given a placebo. The research highlights the potential of nirsevimab as an effective preventive measure against severe RSV disease in young children during their first two years of life.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Child, Preschool; Immunization; Infant, Newborn; Placebos; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Respiratory Tract Infections; Respiratory Syncytial Virus, Human; Clinical Trial

Institutions: AstraZeneca; Ben-Gurion University of the Negev

---

More like this

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants 2022 · Johns Hopkins University, AstraZeneca, Ben-Gurion University of the Negev, Quirónsalud Málaga Hospital Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants 2023 · Northwestern University, University of the Witwatersrand, AstraZeneca, Quirónsalud Málaga Hospital, Medical University of Plovdiv, Ben-Gurion University of the Negev Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season 2024 · Ben-Gurion University of the Negev, Johns Hopkins University, AstraZeneca, Quirónsalud Málaga Hospital, Medical University of Plovdiv, University of the Witwatersrand

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---